QI
KDNY

QS Investors’s Chinook Therapeutics, Inc. Common Stock KDNY Stock Holding History

QS Investors’s Portfolio KDNY Stock Details KDNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-460
Closed -$6K – 1607
2020
Q2 		$6K Hold
460
– – ﹤0.01% 1607
2020
Q1 		$7K Sell
460
-120
-21% -$1.42K ﹤0.01% 1574
2019
Q4 		$4K Hold
580
– – ﹤0.01% 1603
2019
Q3 		$4K Hold
580
– – ﹤0.01% 1616
2019
Q2 		$5K Buy
580
+280
+93% +$4.26K ﹤0.01% 1601
2019
Q1 		$6K Buy
+300
New +$5.23K ﹤0.01% 1591

Other funds holding KDNY

VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return

QS Investors's KDNY Position: Q3 2020 in Review

QS Investors sold out of Chinook Therapeutics, Inc. Common Stock (KDNY) in Q3 2020, closing a stake of 460 shares — an estimated $6K sold.

QS Investors first reported a position in KDNY in Q1 2019 and held it in 6 quarters. The position peaked at $7K in Q1 2020. 70 funds tracked by Wall St. Rank hold KDNY as of Q3 2020.

  • QS Investors reported no remaining Chinook Therapeutics, Inc. Common Stock position as of Q3 2020 after selling out during the quarter.
  • QS Investors sold 460 Chinook Therapeutics, Inc. Common Stock shares in Q3 2020, an estimated $6K.
  • QS Investors first reported a position in Chinook Therapeutics, Inc. Common Stock in Q1 2019 and held it in 6 quarters.
  • QS Investors's Chinook Therapeutics, Inc. Common Stock position peaked at $7K in Q1 2020.
  • 70 funds tracked by Wall St. Rank held Chinook Therapeutics, Inc. Common Stock as of Q3 2020.

Based on QS Investors's 13F filing for Q3 2020, filed 12 Nov 2020.